Deutsche Bank AG Reaffirms Buy Rating for AstraZeneca plc (AZN)

Deutsche Bank AG reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Friday. Deutsche Bank AG currently has a GBX 5,600 ($73.66) target price on the biopharmaceutical company’s stock.

AZN has been the subject of several other reports. Liberum Capital reaffirmed a buy rating and issued a GBX 4,800 ($63.13) price objective on shares of AstraZeneca plc in a research report on Tuesday, September 5th. HSBC Holdings plc increased their price objective on shares of AstraZeneca plc from GBX 4,100 ($53.93) to GBX 4,150 ($54.58) and gave the company a reduce rating in a research report on Monday, October 9th. UBS AG set a GBX 4,550 ($59.84) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research report on Monday, October 23rd. Jefferies Group LLC increased their price target on shares of AstraZeneca plc from GBX 4,350 ($57.21) to GBX 4,800 ($63.13) and gave the stock a hold rating in a report on Monday, September 11th. Finally, Shore Capital reiterated a hold rating on shares of AstraZeneca plc in a report on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company. AstraZeneca plc currently has a consensus rating of Hold and an average price target of GBX 5,247.18 ($69.01).

Shares of AstraZeneca plc (AZN) traded up GBX 68.50 ($0.90) during trading on Friday, hitting GBX 4,938.50 ($64.95). 1,257,664 shares of the company traded hands, compared to its average volume of 1,940,000. AstraZeneca plc has a 52-week low of GBX 3,996 ($52.56) and a 52-week high of GBX 5,520 ($72.60).

WARNING: “Deutsche Bank AG Reaffirms Buy Rating for AstraZeneca plc (AZN)” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.themarketsdaily.com/2017/11/13/deutsche-bank-ag-reaffirms-buy-rating-for-astrazeneca-plc-azn.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply